Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
0.8424
+0.0357 (4.43%)
At close: Jul 8, 2025, 4:00 PM
0.9000
+0.0576 (6.84%)
After-hours: Jul 8, 2025, 7:37 PM EDT
Prelude Therapeutics Market Cap
Prelude Therapeutics has a market cap or net worth of $47.56 million as of July 8, 2025. Its market cap has decreased by -77.63% in one year.
Market Cap
47.56M
Enterprise Value
-33.59M
1-Year Change
-77.63%
Ranking
Category
Stock Price
$0.84
Market Cap Chart
Since the IPO on September 25, 2020, Prelude Therapeutics's market cap has decreased from $806.64M to $47.56M, a decrease of -94.10%. That is a compound annual growth rate of -44.67%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jul 7, 2025 | 45.55M | -35.09% |
| Dec 31, 2024 | 70.17M | -73.80% |
| Dec 29, 2023 | 267.79M | -6.83% |
| Dec 30, 2022 | 287.43M | -50.22% |
| Dec 31, 2021 | 577.35M | -80.97% |
| Dec 31, 2020 | 3.03B | 276.02% |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 698.13B |
| Johnson & Johnson | 374.84B |
| AbbVie | 335.21B |
| Novo Nordisk | 313.36B |
| UnitedHealth Group | 279.13B |
| Novartis AG | 240.15B |
| Abbott Laboratories | 232.02B |
| AstraZeneca | 217.48B |